Drug Profile
Research programme: cancer therapeutics - SHAL Technologies
Alternative Names: SH 7113; SH 7133; SH 7139; SHALsLatest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator SHAL Technologies
- Developer Lawrence Livermore National Laboratory; SHAL Technologies; University of california davis medical center
- Class Small molecules
- Mechanism of Action HLA-DR10 antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Leukaemia in USA (unspecified route)
- 24 Aug 2023 Discontinued - Preclinical for Non-Hodgkin's lymphoma in USA (unspecified route)
- 28 Aug 2019 No recent reports of development identified for preclinical development in Leukaemia in USA